Thalidomide

Reproductive and Developmental Toxicology

Volumn , Issue , 2011, Pages 395-403

  Vargesson, Neil ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884431657     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-382032-7.10031-1     Document Type: Chapter

References (74)

1. B.M. Ances (2002) New concerns about thalidomide. Obstetr Gynaecol 99 125-128
2. Y. Ando, E. Fuse and W.D. Figg (2002) Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 8 1964-1973
3. K.S. Bauer, S.C. Dixon and W.D. Figg (1998) Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55 1827-1834
4. J.B. Boylen, H.H. Horne and W.J. Johnson (1963) Teratogenic effects of thalidomide and related substances. Lancet 1 552
5. C.P. Castaneda, J.B. Zeldis, J. Freeman, C. Quigley, N.A. Brandenburg and R. Bwire (2008) RevAssist: a comprehensive risk minimization programme for preventing fetal exposure to lenalidomide. Drug Saf 31 743-752
6. E.E. Castilla, P. Ashton-Prolla, E. Barreda-Mejia, D. Brunoni, D.P. Cavalcanti, J. Correa-Neto, J.L. Delgadillo, M.G. Dutra, T. Felix, A. Giraldo, N. Juarez, J.S. Lopez-Camelo, J. Nazer, I.M. Orioli, J.E. Paz, M.A. Pessoto, J.M. Pina-Neto, R. Quadrelli, M. Rittler, S. Rueda, M. Saltos, O. Sánchez and L. Schüler (1996) Thalidomide, a current teratogen in South America. Teratology 54 273-277
7. G. Chamberlain (1989) The obstetric problems of the thalidomide children. Brit Med J 298 6
8. J.F. Cullen (1964) Ocular defects in thalidomide babies. Bri J Ophthalmol 48 151-153
9. S. Cundari and G. Cavaletti (2009) Thalidomide chemotherapy-induced peripheral neuropathy: actual status and new perspectives with thalidomide analogues derivatives. Mini Rev Med Chem 9 760-768
10. R. Cuthbert and A.L. Speirs (1963) Thalidomide induced malformations – a radiological survey. Clin Radiology XX 163-169
11. R.J. D'Amato, M.S. Loughnan, E. Flynn and J. Folkman (1994) Thalidomide is an inhibitor of angiogenesis. Proc Nat Acad Sci USA 91 4082-4085
12. M. Ema, R. Ise, H. Kato, S. Oneda, A. Hirose, M. Hirata-Koizumi, A.V. Singh, T.B. Knudsen and T. Ihara (2010) Fetal malformations and early embryonic gene expression response in cynomolgus monkeys maternally exposed to thalidomide. Reprod Toxicol 29 49-56
13. T. Eriksson, S. Björkman and P. Höglund (2001) Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 57 365-376
14. M.E. Franks, G.R. Macpherson and W.G. Figg (2004) Thalidomide review. Lancet 363 1802-1811
15. J.L. Galloway, I. Delgado, M.A. Ros and C.J. Tabin (2009) A reevaluation of x-irradiation-induced phocomelia and proximodistal limb patterning. Nature 460 400-404
16. C. Galustian and A. Dalgleish (2009) Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin Pharmacother 10 125-133
17. J.N. Gordon and P.M. Goggin (2003) Thalidomide and its derivatives: emerging from the wilderness. Postgrad Med J 79 127-132
18. K.L. Hallene, E. Oby, B.J. Lee, S. Santaguida, S. Bassanini, M. Cipolla, N. Marchi, M. Hossain, G. Battaglia and D. Janigro (2006) Prenatal exposure to thalidomide, altered vasculogenesis, and CNS malformations. Neuroscience 142 267-283
19. J.M. Hansen, S.-G. Gong, M.A. Philbert and C. Harris (2002) Misregulation of gene expression in the redox-sensitive NF-kB-dependent limb outgrowth pathway by thalidomide. Dev Dyn 255 186-194
20. J.M. Hansen and C. Harris (2004) A Novel Hypothesis for thalidomide-induced limb teratogenesis: redox misregulation of the NF-κB pathway. Antioxid Redox Signal 6 1-14
21. L. Henkel and H. Willert (1969) Dysmelia – a classification and a pattern of malformation in a group of congenital defects of the limbs. J Bone Joint Surgery 51 399-414
22. T. Ito, H. Ando, T. Suzuki, T. Ogura, K. Hotta, Y. Imamura, Y. Yamaguchi and H. Handa (2010) Identification of a primary target of thalidomide teratogenicity. Science 327 1345-1350
23. W.H. James (1965) Teratogenic properties of thalidomide. Br Med J 2 1064
24. A. Jurand (1966) Early changes in limb buds of chick embryos after thalidomide treatment. J Embryol Exp Morphol 16 289-300
25. T. Kajii, M. Kida and K. Takahashi (1973) The effect of thalidomide intake during 113 human pregnancies. Teratology 8 163-166
26. F.O. Kelsey (1967) Events after thalidomide. J Dental Res 46 1201-1205
27. F.O. Kelsey (1988) Thalidomide update: regulatory aspects. Teratology 38 221-226
28. J. Knobloch, I. Schmitz, K. Götz, K. Schulze-Osthoff and U. Rüther (2008) Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death. Molec Cell Biol 28 529-538
29. J. Knobloch, J.D. Shaughnessy and U. Rüther (2007) Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signalling pathway. FASEB J 21 1410-1421
30. F. Lebrin, S. Srun, K. Raymond, S. Martin, S. van den Brink, C. Freitas, C. Breant, T. Mathivet, B. Larriveel, J.-L. Thomas, H.M. Arthur, C.J.J. Westermann, F. Disch, J.J. Mager, R.J. Snijder, A. Eichmann and C. Mummery (2010) Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nature Med 16 420-429
31. I.M. Leck and E.L.M. Millar (1962) Incidence of malformations since the introduction of thalidomide. Br Med J 2 16-20
32. W. Lenz (1962) Thalidomide and congenital abnormalities. Lancet 1 271-272
33. W. Lenz (1988) A short history of thalidomide embryopathy. Teratology 38 203-215
34. W. Lenz and K. Knapp (1962) Foetal malformations due to thalidomide. Ger Med Mon 7 253-258
35. E.R. Lepper, N.F. Smith, M.C. Cox, C.D. Scripture and W.D. Figg (2006) Thalidomide metabolism and hydrolysis: mechanisms and implications. Curr Drug Metab 7 677-685
36. G. Livingstone (1965) Congenital ear abnormalities due to thalidomide. Proc Royal Soc Med Otology Section 58 493-497
37. W.G. McBride (1976) Studies of the etiology of thalidomide dysmorphogenesis. Teratology 14 71-88
38. W.G. McBride (1961) Thalidomide and congenital malformations. Lancet 1358
39. S. Majumder, M. Rajaram, A. Muley, H.S. Reddy, K.P. Tamilarasan, G.K. Kolluru, S. Sinha, J.H. Siamwala, R. Gupta, R. Ilavarasan, S. Venkataraman, K.C. Sivakumar, S. Anishetty, P.G. Kumar and S. Chatterjee (2009) Thalidomide attenuates nitric-oxide driven angiogenesis by interacting with soluble guanylyl cyclase. Br J Pharmacol 158 1720-1734
40. M.T. Miller and K. Strömland (1999) Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses. Teratology 60 306-321
41. M.T. Miller, K. Strömland, L. Ventura, M. Johansson, J.M. Bandim and C. Gillberg (2005) Autism associated with conditions characterized by developmental errors in early embryogenesis: a mini review. Int J Dev Neurosci 23 201-219
42. R. Neubert, N. Hinz, R. Thiel and D. Neubert (1996) Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide. Life Sci 58 295-316
43. C.G.H. Newman (1985) Teratogen update: clinical aspects of thalidomide embryopathy – a continuing preoccupation. Teratology 32 133-144
44. C.G. Newman (1986) The thalidomide syndrome: risks of exposure and spectrum of malformations. Clin Perinatol 13 555-573
45. S.S.W. Ng, M. Gutschow, M. Weiss, S. Hauschildt, U. Teubert, T.K. Hecker, F.A. Luzzio, E.A. Kruger, K. Eger and W.D. Figg (2003) Antiangiogenic activity of N-substituted and tetra-fluorinated thalidomide analogues. Cancer Res 63 3189-3194
46. F.J.R. Paumgartten (2006) Thalidomide embryopathy cases in Brazil after 1965. Rep Tox 22 1-2
47. A.C. Peltier and J.W. Russell (2006) Advances in understanding drug induced neuropathies. Drug Saf 29 23-30
48. M.S. Raab, K. Podar, I. Breitkreutz, P.G. Richardson and K.C. Anderson (2009) Multiple myeloma. Lancet 374 324-339
49. S.V. Rajkumar (2004) Thalidomide: tragic past and promising future. Mayo Clinic Proc 79 899-903
50. E.P. Sampaio, E.N. Sarno, R. Galilly, Z.A. Cohn and G. Kaplan (1991) Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 173 699-703
51. L. Schuler-Faccini, R.C.F. Soares, A.C. Sousa, C. Maximino, E. Luna, I.V.D. Schwartz, C. Waldman and E.E. Castilla (2007) New cases of thalidomide embryopathy in Brazil. Birth Def Res (Part A) 79 671-672
52. J. Sheskin (1965) Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 6 303-306
53. R.W. Smithells (1962) Thalidomide and malformations in Liverpool. Lancet 1270-1273
54. R.W. Smithells (1973) Defects and disabilities of thalidomide children. Brit Med J 1 269-272
55. R.W. Smithells and I. Leck (1963) The incidence of limb and ear defects since the withdrawal of thalidomide. Lancet 1095-1097
56. R.W. Smithells and C.G. Newman (1992) Recognition of thalidomide defects. J Med Genet 29 716-723
57. B.J. Soules (1966) Thalidomide victims in a rehabilitation centre. Am J Nursing 66 2023-2026
58. A.L. Speirs (1962) Thalidomide and congenital abnormalities. Lancet 303-305
59. T.D. Stephens, C.J.W. Bunde and B.J. Fillmore (2000) Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 59 1489-1499
60. T.D. Stephens and B.J. Fillmore (2000) Hypothesis: thalidomide embryopathy – proposed mechanism of action. Teratology 61 189-195
61. T.D. Stephens (1988) Proposed mechanisms of action in thalidomide embryopathy. Teratology 38 229-239
62. C. Tabin and L. Wolpert (2007) Rethinking the proximodistal axis of the vertebrate limb in the molecular era. Genes Dev 21 1433-1442
63. K.P. Tamilarasan, G.K. Kolluru, M. Rajaram, M. Indhumathy, R. Saranya and S. Chatterjee (2006) Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells. BMC Cell Biology 7 1-13
64. H.B. Taussig (1962) Thalidomide and phocomelia. J Am Acad Paed 30 654-659
65. S.K. Teo, K.E. Resztak, M.A. Scheffler, K.A. Kook, J.B. Zeldis, D.I. Stirling and S.D. Thomas (2002) Thalidomide in the treatment of leprosy. Microb Infect 4 1193-1202
66. C. Therapontos, L. Erskine, E. Gardner, W.D. Figg and N. Vargesson (2009) Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci USA 106 8573-8578
67. M. Towers and C. Tickle (2009) Generation of pattern and form in the developing limb. Int J Dev Biol 53 805-812
68. S. Tseng, G. Pak, K. Washenik, M.K. Pomeranz and J. Shupack (1996) Rediscovering thalidomide: a review of its mechanism of action, side effects and potential uses. J Am Acad Derm 35 969-979
69. A. Vacca, C. Scavelli, V. Montefusco, G. Pietro, A. Neri, M. Mattioli, S. Bicciato, B. Nico, D. Ribatti, F. Dammacco and P. Corradini (2005) Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 23 5334-5346
70. N. Vargesson (2009) Thalidomide-induced limb defects: resolving a 50 year old puzzle. BioEssays 31 1327-1336
71. N. Vargesson (2003) Vascularization of the developing chick limb bud: role of the TGFbeta signalling pathway. J Anat 202 93-103
72. N.A. Warfel, E.R. Lepper, C. Zhang, W.D. Figg and P.A. Dennis (2006) Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. Clin Cancer Res 12 3502-3509
73. T. Yabu, H. Tomimoto, Y. Taguchi, S. Yamaoka, Y. Igarashi and T. Okazaki (2005) Thalidomide-induced antiangiogenic action is mediated through depletion of VEGF receptors, and is antagonized by spingosine-1-phosphate. Blood 106 125-134
74. R. Zeller (2010) The temporal dynamics of vertebrate limb development, teratogenesis and evolution. Curr Opin Genet Dev. In press